Prior to founding ImmBio, Dr Colaço was Director of Intellectual Property (IP) for the biotechnology company Quadrant Healthcare plc, where he was responsible for development of the IP portfolio that formed the basis of its successful listing on the London Stock Exchange and acquisition by Elan. Dr Colaço was responsible for generating the IP that formed their biomolecule stabilisation and delivery technology. In addition to his industry experience, Dr Colaço has worked in a number of leading instituations, including the University of Cambridge Medical School. He has a degree in Biochemistry from the University of London and PhD from the National Institute of Medical Research, London.
The immunobiology of immunotherapy
Cancer Immunotherapy is a paradigm shift in cancer treatment which is now being recognised as a potentially curative treatment. Dr Colaco will summarise current approaches and present the approach to effective personalised cell-based cancer immunotherapy being initiated in Cambridge.
EVEN MORE SEMINARS
Prof Samuel Janes University College London Hospitals
Mylaine Riobe MD, FABOIM, FACOG Riobe Institute of Integrative Medicine
Cancer is not random! Evolving mechanisms for cancer causation and prevention
Rob Duncombe The Christie NHS Foundation Trust
Medicine Optimisation in Oncology. How to achieve best value.
Cheng Boon Worcestershire Royal Hospital
Consultant Clinical Oncologist, GI and Head & Neck
Chris Curtis The Swallows Head & Neck Cancer Charity
A patient’s journey ‘Cancer to the palace in 6yrs’